The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

OBJECTIVE The role of osteoprotegerin (OPG) and its receptor activator of nuclear factor kappaB legend (RANKL) in the regulation of bone in humans remain unclear. We examined the sex-specific associations of serum OPG, RANKL, and their ratio with bone mineral density (BMD) in older adults. DESIGN Participants were 681 community-dwelling adults, ages 45-90 years, who had serum OPG and RANKL measured and bone density scans in 1988-1991, with follow-up scans 5 and/or 10 years later. METHODS Analyses were sex-specific; women using and not using estrogen were evaluated separately. Cross-sectional analyses used multivariable regression models; longitudinal analyses used repeated measures mixed effects models. RESULTS In cross-sectional analyses, age- and weight-adjusted serum OPG levels were significantly positively associated with BMD at the lumbar spine in men, and at the femoral neck, total hip, and lumbar spine in women using estrogen, but not in non-users of estrogen. RANKL concentrations were significantly and inversely associated with BMD in men only, and at the total hip. Neither OPG nor RANKL was significantly associated with bone loss. Results for the RANKL/OPG ratio were the same as those for RANKL alone. CONCLUSIONS These results suggest a modulatory effect of both endogenous and exogenous sex hormones on the biologic interaction of OPG, RANKL, and bone.

[1]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[2]  Marcia Lane,et al.  Lifetime Leisure Exercise and Osteoporosis , 1995 .

[3]  E. Kobyliansky,et al.  Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. , 2004, European journal of endocrinology.

[4]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[5]  Won-Young Lee,et al.  The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women , 2004, Clinical endocrinology.

[6]  H. Melhus.  Soluble RANKL and risk of nontraumatic fracture. , 2004, JAMA.

[7]  I. Reid,et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.

[8]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[9]  M. Muñoz-Torres,et al.  The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women , 2005, Osteoporosis International.

[10]  P. Pietschmann,et al.  Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.

[11]  E. Barrett-Connor,et al.  Effect of active and passive smoking on ventilatory function in elderly men and women. , 1996, American journal of epidemiology.

[12]  J. Glowacki,et al.  Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. , 2000, Biochemical and biophysical research communications.

[13]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[14]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Barrett-Connor,et al.  Measures of Renal Function, BMD, Bone Loss, and Osteoporotic Fracture in Older Adults: The Rancho Bernardo Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[17]  G. Sigurdsson,et al.  Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover , 2005, Osteoporosis International.

[18]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[19]  R. Eastell,et al.  Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  K. Ikeda,et al.  Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  E. Barrett-Connor,et al.  Leisure Time Exercise and Lipid and Lipoprotein Levels in an Older Population , 1990, Journal of the American Geriatrics Society.

[22]  S. Cummings,et al.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[24]  S. Khosla,et al.  Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. , 2002, European journal of endocrinology.

[25]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[26]  L. Melton,et al.  Correlates of Osteoprotegerin Levels in Women and Men , 2002, Osteoporosis International.

[27]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[28]  K. Chihara,et al.  Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[30]  P. Härkönen,et al.  Estrogen and Testosterone Use Different Cellular Pathways to Inhibit Osteoclastogenesis and Bone Resorption , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  R. Eastell,et al.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  S. Ingles,et al.  Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study. , 1995, American journal of epidemiology.

[33]  Toshio Matsumoto,et al.  17β-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-α. , 2001, Endocrinology.

[34]  J. Gallagher,et al.  Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  S. Kido,et al.  17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. , 2001, Endocrinology.

[36]  W. Woloszczuk,et al.  Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. , 2003, Clinical laboratory.

[37]  Sun Woo Kim,et al.  Circulating osteoprotegerin and receptor activator of NF‐κB ligand system are associated with bone metabolism in middle‐aged males , 2005, Clinical endocrinology.

[38]  E. Barrett-Connor,et al.  Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. , 1992, JAMA.

[39]  P. Delmas,et al.  Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[41]  W. Fraser,et al.  Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. , 2003, Clinical chemistry.

[42]  P. Kostenuik,et al.  Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. , 2005, Bone.